跳至主要内容
临床试验/NCT05402254
NCT05402254已完成不适用

Evaluation of the Impact of a Pharmacovigilance Program Led by Advanced Practice Nursing on Patients and Professionals at Hospital: Intervention Study

Natalia Rodriguez Galan1 个研究点 分布在 1 个国家目标入组 395 人开始时间: 2022年5月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
395
试验地点
1
主要终点
Adverse drug event

研究概览

简要总结

HYPOTHESIS An advanced practice nursing intervention in the area of pharmacovigilance performed on patients and professionals improves the identification and reporting of suspected adverse drug reactions (ADR) and improves the overall experience of hospitalized patients.

详细描述

PRIMARY OBJETIVES

  1. To assess whether an advanced nursing intervention improves the identification and reporting of suspected ADR.

SECONDARY OBJECTIVES

  1. To determine if an advanced nursing intervention improves the experience related to the use of medications measured through the QExPac-21 patient experience questionnaire.
  2. Identify which factors associated with medications increase the risk of ADRs and the characteristics of the patients.
  3. Know the incidence and describe ADRs: severity, preventability, and causality using validated scales.
  4. Describe the degree of nursing intervention according to the North American Nursing Diagnosis Association (NANDA) Taxonomy, and the classification of nursing interventions (NIC) Related to drug use.
  5. Quantify the number of interconsultation generated by patients and professionals related to the use of drugs.
  6. Determine the degree of adherence and compliance with the regimens prescribed to the patients.

STUDY DESIGN Prospective, randomized and controlled study of an intervention that compares a group of patients according to the usual practice of the nursing care process, against another on which a more intensive nursing intervention is carried out for the identification and notification of ADRs. It is carried out on a representative sample of patients admitted to a tertiary level hospital with 860 beds of the Madrid Health Service during the year 2022.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
None

入排标准

性别
All
接受健康志愿者
是

入选标准

  • •Patients with pharmacological treatment.
  • •Patients of both sexes aged between 0 and 100 years.
  • •Patients admitted to medical or surgical hospitalization units or emergency services for at least 24 hours.
  • •Patients who have received the information and agreed to participate in the study.

排除标准

  • •Patients included in other clinical trials or drug studies at the time of selection.
  • •Patients with significant cognitive impairment, without adequate family support or primary caregiver.
  • •Patients and/or caregivers who, once offered to participate in the study, do not give their consent
  • •Impossibility of communication due to language barriers or other biopsychosocial problems.

研究组 & 干预措施

Pharmacovigilance Program

Experimental

Intensive nursing intervention is carried out for the identification and notification of ADE

干预措施: Pharmacovigilance Program (Other)

Control

No Intervention

The Usual practice of the nursing care process

结局指标

主要结局

Adverse drug event

时间窗: Seven months

Number of identified adverse drug event

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Natalia Rodriguez Galan

principal investigator

Hospital San Carlos, Madrid

研究点 (1)

Loading locations...

相似试验

Impact of a Pharmacovigilance Program Led by... | 临床试验